Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Common Equity (2022 - 2025)

Historic Common Equity for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $43.7 million.

  • Orchestra BioMed Holdings' Common Equity fell 536.58% to $43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.7 million, marking a year-over-year decrease of 536.58%. This contributed to the annual value of $33.0 million for FY2024, which is 5156.3% down from last year.
  • Orchestra BioMed Holdings' Common Equity amounted to $43.7 million in Q3 2025, which was down 536.58% from $295000.0 recorded in Q2 2025.
  • Over the past 5 years, Orchestra BioMed Holdings' Common Equity peaked at $99.8 million during Q1 2023, and registered a low of -$6.1 million during Q3 2022.
  • Its 4-year average for Common Equity is $41.0 million, with a median of $44.1 million in 2024.
  • Per our database at Business Quant, Orchestra BioMed Holdings' Common Equity skyrocketed by 237764.57% in 2023 and then crashed by 9933.14% in 2025.
  • Over the past 4 years, Orchestra BioMed Holdings' Common Equity (Quarter) stood at $52.5 million in 2022, then increased by 29.52% to $68.0 million in 2023, then tumbled by 51.56% to $33.0 million in 2024, then soared by 32.71% to $43.7 million in 2025.
  • Its Common Equity stands at $43.7 million for Q3 2025, versus $295000.0 for Q2 2025 and $16.9 million for Q1 2025.